Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor

Medicilon won the "Top 50 China Best Employer Award 2021"

Medicilon assisted EP4 Receptor Antagonist YY001 Obtained Clinical Approval

On March Bio Ray Lab's self-developed new-generation EP4 receptor small molecule antagonist YY001 clinical trial application was officially approved by the National Medical Products Administration (NMPA), agreeing to conduct Phase 1 clinical trials for advanced solid tumors.

Medicilon was selected as a constituent stocks of the "STAR 50" Index

Shanghai Medicilon Inc. (Medicilon) was selected as a constituent stock of the "STAR 50" Index.

Medicilon has Won Praises and Awards From Multiple Partners Again

Medicilon has overcome technical problems in R&D, delivered more than expected “answer sheets”, promoted the progress of projects efficiently, and increased collaboration efforts.  Medicilon has won the trust and awards of clients with their strength and hard work.